Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 10, 2013, Pages 1687-1697

  Aspinwall, Lisa G ^a,c   Taber, Jennifer M ^a   Leaf, Samantha L ^a   Kohlmann, Wendy ^c   Leachman, Sancy A ^b,c  

^a Departments of Psychology   (United States)

^b Departments of Dermatology   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16;

ADULT; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEALTH INSURANCE; HETEROZYGOTE; HUMAN; MALE; MELANOMA; MORTALITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHENOTYPE; POPULATION RISK; PREVALENCE; PRIORITY JOURNAL; SELF EXAMINATION; SKIN EXAMINATION; SKIN SELF EXAMINATION; TOTAL BODY SKIN EXAMINATION;

EARLY DETECTION OF CANCER; FEMALE; GENETIC COUNSELING; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TIME FACTORS;

EID: 84885587396     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0422     Document Type: Article

References (21)

1. Khoury MH, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9:665-74.
2. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature 2003;422:835-47.
3. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
4. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19: 3635-48.
5. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al., (eds). SEER Cancer Statistics Review, 1975-2009, based on November 2011 SEER data submission, posted to the SEER web site. Bethesda, MD: National Cancer Institute; April 2012. Available from: http://seer.cancer.gov/csr/1975-2009- pops09/.
6. Hansen CB, Wadge LM, Lowstuter K, Boucher K, Leachman SA. Clinical germline genetic testing for melanoma. Lancet Oncol 2004; 5:314-9.
7. Aspinwall LG, Leaf SL, Dola ER, Kohlmann W, Leachman SA. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev 2008;17:1510-9.
8. Glanz K, Volpicelli K, Kanetsky PA, Ming ME, Schucter LM, Jepson C, et al. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev 2013;22:607-14.
9. Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med 2009;11:265-78.
10. Christensen KD, Roberts JS, Shalowitz DI, Everett JN, Kim SYH, Raskin L, et al. Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev 2011;20:522-9.
11. Bowen D, Jabson J, Haddock N, Hay J, Edwards K. Skin care behaviors among melanoma survivors. Psychooncology 2012;21: 1285-91.
12. Kasparian NA, McLoone JK, Meiser B. Skin cancer-related prevention and screening behaviors: a review of the literature. J Behav Med 2009; 32:406-28.
13. Mujumdar UJ, Hay JL, Monroe-Hinds YC, Hummer AJ, Begg CB, Wilcox HB, et al. Sun protection and skin self-examination in melanoma survivors. Psychooncology 2009;18:1106-15.
14. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
15. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;258:1148-52.
16. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005;23:7168-77.
17. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. Psychooncology 2013;22:276-89.
18. Aspinwall LG, Leaf SL, Kohlmann W, Dola ER, Leachman SA. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol 2009;60:745-57.
19. Kefford RF, Mann GJ. Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol 2003;15:157-61.
20. Michie S, Weinman J, Miller J, Collins V, Halliday J, Marteau TM. Predictive genetic testing: high risk expectations in the face of low risk information. J Behav Med 2000;25:33-50.
21. Aspinwall LG, Taber JM, Kohlmann W, Leachman SA. Psychological aspects of hereditary cancer risk counseling and genetic testing. In: Carr BI, Steel J, editors. Psychological aspects of cancer: a guide to emotional and psychological consequences of cancer, their causes and their management. New York, NY: Springer; 2013. p. 31-64.